BLCOMEDIUM SIGNALFINANCIAL10-K

BLCO shows mixed financial performance with operating income declining 30% while cash flow from operations improved 22%, amid ongoing uncertainty about separation from parent company Bausch Health.

The significant decline in operating income coupled with widening net losses suggests operational challenges, though the strong improvement in operating cash flow and increased cash position provide some financial stability. The removal of detailed language about the separation from Bausch Health Companies creates uncertainty about the timeline and structure of this strategic transaction.

Comparing 2026-02-18 vs 2025-02-19View on EDGAR →
FINANCIAL ANALYSIS

BLCO's financial picture is mixed, with operating income falling sharply by 30% to $113M and net losses widening to $360M, indicating operational headwinds. However, the company strengthened its liquidity position with cash increasing 26% to $383M and operating cash flow improving 22% to $283M, suggesting better working capital management despite profitability challenges. The increase in current liabilities alongside higher cash levels may reflect timing of payments or operational scaling, but the improved cash generation provides a cushion against the declining profitability metrics.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-30.2%
$162.0M$113.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
+25.6%
$305.0M$383.0M

Cash grew 25.6% — improving liquidity position supports investment and shareholder returns.

Operating Cash Flow
Cash Flow
+22%
$232.0M$283.0M

Operating cash flow grew 22% — strong conversion of earnings to cash, healthy business fundamentals.

Net Income
P&L
-13.6%
-$317.0M-$360.0M

Net income declined 13.6% — review whether driven by operations, interest costs, or non-recurring items.

Current Liabilities
Balance Sheet
+10.5%
$1.7B$1.9B

Current liabilities rose 10.5% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-18
PRIOR — 2025-02-19
ADDED
The number of outstanding shares of the registrant s common shares as of February 11, 2026 was 354,318,198 .
BI-BLADE is a trademark of Medical Instrument Development Laboratories, Inc.
(including on the countries in which we do business and sectors in which we do business (including pharmaceuticals)) and counter-tariffs or other retaliatory measures imposed (or that may be imposed) on the U.S.
military action in Venezuela and the tensions between the U.S.
and Greenland, and other members of the North Atlantic Treaty Organization; and the anticipated separation from Bausch Health Companies Inc.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s common shares as of February 12, 2025 was 352,470,796 .
( BHC ), with BHC directly or indirectly holding 310,449,643 Bausch + Lomb common shares, which represents approximately 88.1% of the issued and outstanding common shares of Bausch + Lomb, as of February 12, 2025.
Bausch + Lomb understands that BHC continues to believe that completing the Separation, which may include the transfer of all or a portion of BHC s remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the Distribution ), the monetization of all or a portion of BHC s ownership interest in Bausch + Lomb, the sale of the Company (a Sale Transaction ) or a combination thereof, makes strategic sense and that BHC continues to evaluate all relevant factors and considerations related to completing the Separation, including those factors described in BHC s public filings.
Segment revenues for the years 2024, 2023 and 2022 were as follows: 2024 2023 2022 (in millions) Amount Pct.
Vision Care $ 2,739 57 % $ 2,543 61 % $ 2,369 63 % Pharmaceuticals 1,209 25 % 836 20 % 681 18 % Surgical 843 18 % 767 19 % 718 19 % Total revenues $ 4,791 100 % $ 4,146 100 % $ 3,768 100 % Comparative segment information for 2024, 2023 and 2022 is further presented in Note 21, SEGMENT INFORMATION to our audited Consolidated Financial Statements.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →